JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Treatment for multiple periorbital eccrine hidrocystomas: botulinum toxin A.

Hidrocystomas are relatively common cystic lesions that can display either apocrine or eccrine differentiation. While numerous treatment modalities exist for solitary hidrocystomas including simple excision, electrodesiccation, and CO2 laser, treatment of multiple hidrocystomas can be challenging. A 38-year-old, black female with a 23-year history of multiple periorbital cystic nodules presented to the clinic with the complaint of lesions that were increasing in size and number. Prior treatment included excision resulting in scarring without significant clinical improvement. Initially, incision and drainage was performed with flattening of the cysts; however, the cystic nodules refilled to baseline by 6 weeks. Subsequently, intralesional botulinum toxin type A was offered as an alternate therapy in conjunction with incision and drainage. The patient reported sustained flattening of the lesions at both 1-month and 4-month follow-up appointments. Intralesional botulinum toxin A offers a novel treatment for patients with multiple hidrocystomas that have failed other therapies.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app